HIV Research to Look Forward to at ICAAC 2014
September 3, 2014
There's another HIV conference right around the corner, the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), which will be held in Washington, D.C., from Sept. 5-9.
While ICAAC covers a range of infectious diseases, there will be many key sessions surrounding HIV this year. Having looked over the program, here's what I think will be the most noteworthy research coming out of the conference, or at least a preview of what to expect, because you never know with these conferences: Sometimes a study or presentation can surprise with its findings.
There will be a poster session on new antiretrovirals, including updated results on cabotegravir (also known as GSK744), the investigational integrase inhibitor being developed both as an oral tablet and as a long-acting (LA) injectable; early results on BMS-986001, an investigational nucleoside reverse transcriptase inhibitor (NRTI); as well as updated results on gene therapy using zinc finger nucleases.
Similarly, there will be a symposium on what's new in antiretroviral therapy, which will feature discussion on what to start, new drugs in the pipeline, and how to reduce pill burden, as well as a review of evidence supporting nucleoside-sparing regimens.
Another session that's sure to grab a lot of attention is the symposium on the road to a cure, which will look at the role of HIV reservoirs in HIV pathogenesis, the prospect of therapeutic immunization and where we are with eradication strategies.
Finally, I think the slide session discussing challenging comorbidities in HIV will also be interesting. The session will include a look at risk factors for COPD (chronic obstructive pulmonary disease), changes in BMD (bone mineral density) that occur with antiretroviral therapy and the significance of HPV (human papillomavirus) among women living with HIV.
In addition, there will certainly be plenty of posters to browse through. Depending on their findings, these could also be clinically important. We'll be sure to cover and report any noteworthy results.
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
Copyright © 2014 Remedy Health Media, LLC. All rights reserved.
This article was provided by TheBodyPRO.com. It is a part of the publication The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014).
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)